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Abstract 
Maternal obesity is associated with adverse outcomes. Placental lipid droplets (LD) have been 
implicated in maternal-fetal lipid transfer but it is not known whether placental LD fat composition 
is modifiable. We evaluated the effects of a diet and physical activity intervention in obese pregnant 
women compared to routine antenatal care (UPBEAT study) on placental LD composition. LD were 
isolated by ultracentrifugation. Total FAs and phospholipids (phosphatidylcholines, PCs; 
sphingomyelins, SMs and lyso-phosphatidylcholines, Lyso-PCs) were analyzed by LC-MS/MS. 
Placenta MFSD2a expression was assessed by western blot. Placental LDs from obese women were 
comprised of predominantly saturated and monounsaturated FAs. TG and Chol composition was 
similar between intervention (n=20) and control (n=23) groups. PCs containing dihomo-ɣ-linolenic 
acid in LD were positively associated with gestational weight gain (P<0.007), and lowered by the 
intervention. In the whole sample, PCs carrying DHA and arachidonic acid were inversely 
associated with placental weight. Placenta MFSD2a expression was associated with DHA cord 
blood metabolites and relationships were observed between LD lipids, especially DHA carrying 
species, and cord blood metabolites. We describe placenta LD composition for the first time and 
demonstrate modest, potentially beneficial effects of a lifestyle intervention on LD FAs in obese 
pregnant women. 
 
Keywords: lipid droplets, placenta, omega-3 fatty acids, phospholipids, randomised controlled trial, 
MFSD2a. 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
3 
 
1. Introduction 
Lipid droplets (LD) are cytosolic depots of neutral lipids that exist in virtually all cell types 
and in all forms of life, from bacteria to mammals [1]. Unlike common cell organelles, LD have a 
unique organization, composed of a neutral lipid core surrounded by a protein-coated phospholipid 
(PL) monolayer [2]. The LD core contains predominantly TGs and sterol esters, but other 
endogenous neutral lipids such as retinol esters may also be present [3]. The monolayer surface 
presents mainly PL, with phosphatidylcholine (PC) being the most abundant, together with a 
varying amount of free cholesterol (Chol) and a long list of embedded proteins [4-6]. 
LD size can change with the cell stage or nutritional status [7]. Most cells types contain a 
set of relatively small LD (<5µm diameter) while supersized LD may be found in white adipose 
tissue cells (>100µm diameter). The formation and composition of LD strongly depends on the 
available FA in the local extracellular and intracellular environment [8-9], affecting the function of 
these particles within specific tissues.  
LD regulation and metabolism have been the focus of attention in tissues such as the heart 
[10], gut [11] or skeletal muscle [12], however, little is known regarding LD composition or 
function in placenta. Extrapolating  from other tissues to the human placenta, variations in maternal 
plasma FAs during pregnancy could affect the formation and composition of placental LD and 
hence the FA materno-fetal transfer process.The possible involvement of placental LD in the 
materno-fetal transfer of FA and in fetal development and growth has not been studied to date 
despite the fundamental role of the placenta in fetal nutrition and the global escalation in maternal 
obesity which is strongly associated with increased risk of fetal macrosomia and large for 
gestational age (LGA) infants. Excessive size at birth leads to problems at delivery and may also be 
a precipitating factor in development of obesity and metabolic syndrome in later life [13-15]. Whilst 
a recent study has reported a 17.5% increase in lipids in the placenta of obese pregnant women 
compared to lean women [16] it is not known whether any of the interventions currently under 
evaluation in obese pregnant women which aim to improve maternal and neonatal outcomes can 
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modify  the placental lipid fat content of the placental lipid storage depots as measured in the LD, or 
affect the transfer of fats from the mother to the developing embryo and fetus [17]. 
The UK Pregnancies Better Eating and Activity Trial (UPBEAT) in 1555 obese pregnant women 
showed  that  a complex behavioural intervention comprising diet and physical activity reduced 
measures of maternal gestational weight gain (GWG), adiposity, and was associated with reduction 
in infant adiposity at 6 months of age [18], although the primary objectives of reducing maternal 
gestational diabetes and LGA were not met [19]. We hypothesised that placenta LD composition 
would be improved by the UPBEAT intervention. In addressing this hypothesis we have described 
for the first time the lipid composition of LD in placenta and evaluated relationships with maternal 
and newborn clinical parameters, and have investigated a potential role of the LD lipid species in 
FA transfer to the fetus. 
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2. Materials and Methods 
2.1. Subjects 
Obese pregnant women (BMI ≥30kg/m2) were recruited from UK antenatal clinics between 15 
weeks and 18 weeks’ plus 6 days of gestation and randomly assigned to either a behavioural 
intervention or standard antenatal care. All participants were older than 16 years and had a singleton 
pregnancy. Exclusion criteria included: unwilling/unable to give informed consent, multiple 
pregnancy, underlying disorders including GDM, type 1 or type 2 diabetes and hypertension. 
Subjects in the intervention arm were invited to attend 8 one-to-one weekly sessions with a health 
trainer to promote a healthier pattern of eating (low glycemic index diet, reduced saturated fat 
intake and reduced free sugars) and increased physical activity. Standard care women attended 
routine antenatal care. All women gave informed consent. The study was approved by the NHS 
Research Ethics Committee (UK Integrated Research Application System; reference 09/H0802/5). 
Full details of the study have been published previously [19]. Clinical and socio-demographic 
characteristics of the sub-group of participants in the present study were representative of the 
women from the main UPBEAT trial participants, with the only significant difference being the 
average age of the women (2 years older in the sub group). 
2.2. Biological samples 
 Placenta samples were collected at delivery from 43 women (23 control and 20 
intervention) delivering at the London Guy’s and St. Thomas’ NHS Foundation Trust trial site. 
Fasting blood samples from the mothers were taken after the intervention period, at between 27 
weeks and 28 weeks plus 6 days of gestation. Mixed cord blood was obtained immediately after 
delivery. Triglycerides, total HDL and LDL cholesterol were evaluated in maternal serum by NMR 
metabolomic profiling, and insulin in maternal plasma by immunoassay [20]. Samples were 
collected as a pool of four imaginary quadrants, rinsed in cold 0.9% NaCl solution and frozen at -
80ºC until analysis. 
2.3. Gestational Weight Gain and Maternal and Neonatal Anthropometry  
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Maternal weight gain during pregnancy was measured and anthropometric measures in 
mother and newborn infant recorded as reported for the main trial [21]. 
2.4. Lipid droplets isolation 
 LD were isolated from placental tissue as previously described [22]. Briefly, 5g of placenta 
were gently rinsed with cold 0.9% NaCl to eliminate blood. Samples were transferred to 12mL 
buffer (25mM tricine, 250mM sucrose, 0.2mM phenylmethylsulfonyl fluoride, pH 7.6) and 
homogenized using a T25 digital Ultra-Turrax® (IKA, Staufen, Germany) disperser for 1min 
followed by homogenization in a tissue grinder Potter-Elvehjem (25 times). Homogenates were 
centrifuged (3,000g, 10min, 4ºC). Supernatants were transferred to an Ultra-Clear centrifuge tube 
(Beckman Coulter, CA, USA) and 2mL buffer (20mM HEPES, 100mM KCl, 2mM MgCl2, pH 7.4) 
were loaded on the top of the tissue homogenate. The supernatants were again centrifuged 
(288,000g, 54min, 4ºC ) in a Beckman Optima XL100 ultracentrifuge equipped with a swinging 
bucket SW41Ti rotor (Beckman Coulter, CA, USA). After centrifugation, the floating white band 
containing LD was collected. Analyses were performed by duplicate; one aliquot was used for TG 
and Chol measures and the other one for FAs quantification. 
2.5. Triglycerides and cholesterol quantification 
 As the LD band is a colloidal suspension, total lipids were initially extracted with 
chloroform:methanol (2:1 v/v) according to Folch et al. [23]. The lipid dry residue was dissolved in 
ultrapure water containing 2% Triton X-100 (Sigma-Aldrich, MO, EEUU). TGs and Chol content 
of LD were quantified by spectrophotometry using commercial kits of determination for liquid 
samples (QCA, Barcelona, Spain). Chol determination included both free Chol and Chol from sterol 
esters quantification. Data were expressed per mg of protein, analyzed by Bradford assay [24] in the 
placenta homogenate. 
2.6. Fatty acids quantification 
 Total lipids from LD were extracted according to the method of Folch et al. [23]. For LD 
total FAs profile, an additional step of FA hydrolysis with 40% KOH during 30min 60ºC was 
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performed before quantification [25]. Lipidome analyses of PCs, SMs and Lyso-PCs from LD, 
maternal plasma and cord blood were performed by LC-MS/MS as described previously [26]. PCs 
were described with (XX:Y/XX:Y) as a characterization of the sn-1/sn-2 FAs (XX, number of 
carbon atoms; Y, number of double bounds). Analyzed PC metabolites were expressed as the sum 
parameter of both FAs (e.g. PC.34:1) and the two single most common FAs combination based on 
previous works (e.g. PC.16:0/18:1) [27-28]. Analyst 1.6.2 software (AB Sciex, Darmstadt, 
Germany) was used for data acquisition. 
2.7. Quality Control 
 Six samples were used as quality control per batch of analyzed samples, 20% intra-batch 
and 30% inter-batch coefficient of variance were used as threshold. Metabolites exceeded these 
coefficients of variance in control samples were excluded from the analyses. 
2.8. Western blot analysis 
 30mg of placenta were homogenized in 0.3mL cell lysis buffer (Cell Signaling Technology, 
MA, EEUU) containing 1mM phenylmethanesulfonyl fluoride [29]. Samples were homogenized in 
a Tissue Lyser LT device (Qiagen Iberia SL, Madrid, Spain). After homogenate centrifugation 
(15min, 10,000g, 4ºC), supernatant with protein lysates was collected and protein quantified by 
Bradford assay [24]. 
Primary rabbit polyclonal antibody against the orphan transporter “Major Facilitator 
Superfamily Domain Containing 2A” (MFSD2a) (Abcam, Cambridge, United Kingdom) and 
primary anti-beta-actin mouse monoclonal antibody (Sigma-Aldrich, MO, EEUU) were used. 
Secondary antibodies were conjugated with horseradish peroxidase (Santa Cruz Biotechnology, TX, 
EEUU). 15μg of protein were resolved on 10% polyacrylamide gels, and transferred onto 
polyvinylidene difluoride membranes (Merck Millipore, Darmstadt, Germany). Membranes were 
blocked with PBS 0.05% Tween-20 (PBS-T) containing 2% bovine serum albumin (1h room 
temperature). Then membranes were incubated with primary antibodies (4ºC overnight). The 
following day, incubation with secondary antibodies conjugated with horseradish peroxidase was 
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performed (room temperature 1h). Proteins were detected using a chemioluminescence kit (Pierce 
ECL 2 Western Blotting Substrate; Thermo Fisher Scientific, MA, EEUU)[30]. Band density was 
determined by densitometry (Image Quant LAS 500 software, GE Healthcare, CA, EEUU). 
Loading controls were used for normalization of protein expression. Beta-actin loading controls 
were used for the normalization of protein expression data. 
2. 9. Statistical analysis 
Anthropometric characteristics, biochemical parameters of mothers and neonates as well as 
LD composition between intervention (n=20) and control (n=23) groups were analyzed by t-test. 
Chi-square test was used for caesarean section rate between groups. Pearson correlations were 
performed in order to assess associations between maternal and newborn/6 month old parameters 
and LD composition/metabolites. SPSS 23.0 software (SPSS, Inc., IL, EEUU) was used for 
statistical analysis of data. Significance level was established as P<0.05. Data are expressed as 
means ± SEM. 
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3. Results 
3.1. Anthropometric Characteristics and Biochemical Parameters 
 In this sub-group of the UPBEAT trial participants (n=43), as reported for the main trial the 
behavioural intervention significantly reduced the glycaemic index of the maternal diet compared to 
those that received a routine antenatal program (Table 1). Fasting plasma TGs were also reduced in 
obese women from the intervention group, however plasma Chol levels and placental weight did not 
differ between groups (Table 1). In this small sample of trial participants, birth weight and 
abdominal circumference were reduced in the intervention group (Table 1), although this was not 
observed in the entire UPBEAT cohort. 
3.2. Lipid Droplets Composition 
TG and Chol content of placental LD was similar between the intervention and control 
groups (Fig. 1A and 1B). In the combined groups, the TG content was 2.5-3 fold higher than Chol. 
The total FA concentration in placental LD showed a significant correlation with the TG content in 
LD (Fig. 1C), indicating a substantial contribution of TGs to the lipid composition of LD particles. 
Total FA in LD, which represent the FA composition of the core plus the envelope of LD 
did not differ between randomised groups (Fig. 2). Total FA in LD predominantly comprised 
saturated FAs, especially palmitic (16:0) and stearic acid (18:0), while LC-PUFAs such as dihomo-
γ-linolenic acid (DGLA, 20:3n-6), arachidonic acid (ARA, 20:4n-6) and DHA (22:6n-3) were less 
abundant (Fig. 2). Saturated FAs represented more than 65% of total FAs of LD while LC-PUFAs 
less than 15% in both groups. 
FAs in PLs represent the envelope or surface of LD and comprise PCs, sphingomyelins 
(SMs), lysophospatidyl cholines (lyso PCs) and others. PCs represented approximately 2.1-2.4% of 
the total FA content of LD, SMs 0.8-1% of total FA content, while the contribution of Lyso-PCs 
was very low (0.03-0.05%). PCs containing DGLA (20:3n-6) were lower in the intervention group 
than in controls and the DGLA content was positively related to GWG (PC.16:0/20:3 and 
PC.18:0/20:3, R=0.44 / 0.53 and P=0.007 / <0.001 respectively). In contrast, PCs carrying ARA 
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were inversely correlated with GWG (PC.16:0/20:4 and PC.18:0/20:4, R= -0.37 / -0.36 and P= 
0.027 / 0.027 respectively). 
SMs mainly comprised saturated and monounsaturated species, with SM.16:0 being the 
most abundant (Table 2). No major differences were observed between intervention and control 
subjects, with the exception of SM.16:1n-7 and SM.17:0 but their contribution to the SM profile 
was low. Subjects in the intervention arm had a higher proportion of saturated SMs and lower 
monounsaturated SMs metabolites compared to controls. SM.24.2n-6 was positively associated with 
birthweight (R=0.45, P=0.003), newborn mid arm circumference (R=0.50, P=0.004) and abdominal 
circumference at birth (R=0.65, P<0.001). 
The content of LC-PUFAs in PCs of LD, especially those carrying ARA (Fig. 3A and 3B) 
and DHA (Fig. 3C) was inversely related to placental weight. These LC-PUFAs were also 
positively associated with the corresponding PCs in cord blood (Table 3). Maternal total DHA 
serum concentration correlated with PC carrying DH  in LD (PC.16:0/22:6, R=0.35, P=0.033). 
Since LysoPCs are known to play an important role in DHA placental uptake, the LD 
LysoPC profile was also analyzed. The LysoPC.18:1 (oleic acid) percentage was lower in the 
intervention arm when compared to controls but no other LysoPCs were different (Table 2). Among 
all Lyso-PCs, Lyso-DHA alone correlated with its lyso-FA form in cord blood. 
As Lyso-DHA transport has been associated with MFSD2a carrier in placenta, we analyzed 
MFSD2a but placental expression did not differ between groups (Fig. 4A). MFSD2a protein was 
inversely related to the total FAs in LD (Fig. 4B), which might indicate a lower expression of this 
protein when increasing fat stores of LD. Maternal DHA concentration in serum was positively 
associated with placenta MFSD2a (R=0.37, P=0.026) and placental MFSD2a expression was 
associated with cord blood metabolites carrying DHA such as PC.18:0/22:6 (Fig. 4C) and followed 
the same trend for PC.16:0/22:6 (R=0.293, P=0.078) and non-esterified DHA (R=0.328, P=0.051), 
supporting the role of this protein for DHA transfer across the placenta. There was no correlation 
between placental MFSD2a and cord blood lyso-DHA (R=0.028, P=0.868). 
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4. Discussion 
 This study explored placental LD composition in a subset of subjects from the 
UPBEAT trial of obese pregnant women undergoing a complex behavioural intervention 
comprising nutritional coaching and physical activity advice vs. routine antenatal care. Differences 
observed in LD lipid species following the intervention suggest that this life style intervention has 
the potential to modify lipid storage in the placenta. Moreover, we have described for the first time 
the individual FA profile of these intracellular particles in placental tissue of obese women. 
There were no differences either in LD TG or Chol content between randomisation arms. 
As anticipated from LDs in other tissues, TGs were the predominant LD lipid class, being strongly 
correlated with the total FA content. A recent study has shown higher TG accumulation in placenta 
in obese women compared to lean women [31]. The authors also reported a positive correlation 
between maternal pre-pregnancy BMI and the up-regulation of six genes involved in lipid 
metabolism in placental tissue, notably CGI-58, a co-activator of adipose TG lipase. Moreover, 
CGI-58 correlated with the maternal fasting insulin concentration, highlighting a potential role of 
pre-gravid obesity on placenta lipid metabolism, even with glucose and serum TGs levels within 
normal range [31]. In this sub-study (but not the overall trial), maternal serum TGs were lower in 
the intervention group, but this reduction was not reflected in the LD TG content. It is possible 
therefore that in obese pregnant women, placental LD may reflect placental FA synthesis in 
placenta arising from excess of glucose associated with insulin resistance, rather than maternal TG 
uptake from serum. 
Saturated and monounsaturated FAs were the predominant components in the total lipids of 
LD. These can be synthesized de novo from glucose, but also from non-esterified FAs (NEFAs); 
enhanced FA esterification and TG deposition in placenta LD has been reported following 
incubation with NEFAs [32-34] which show a higher capacity to influence FA deposition than 
glucose or insulin. Moreover, since placental tissue has low desaturase activity, required for LC-
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PUFA biosynthesis [35], this may also contribute to the FAs pattern observed in placental LD, i.e a 
high content of saturated and monounsaturated FAs. 
PLs comprise about 2% of total FAs in placental LD, similar to the composition observed in 
LD from other cell types [36-37]. PC has been described as the major PL class in LD structures, 
followed by phosphatidylethanolamine and phosphatidylinositol species [5, 38]. In the placenta LDs 
from the obese women, a relatively high proportion of SMs was found compared to the PC content 
(~30%) while additional PL types were not quantified. Other authors have also reported a high 
content of SMs in LD from mouse adipocytes [36]. PL metabolism in LD is, however, not 
completely understood. The presence in the monolayer surface of key enzymes involved in PC 
synthesis e.g. phosphocholine cytidylyltransferase [39] responsible for CDP-choline synthesis, a 
rate-limiting step in the Kennedy pathway of PC synthesis, implies a role of LD in PL cell 
homeostasis and LD maintenance [38-39]. 
The percentage of DGLA (20:3n-6) in LD PCs was lower in the intervention group 
compared to controls. DGLA has previously been related to insulin resistance and the promotion of 
adiposity in adults and children [40-42]. Two cohort studies have found that the maternal DGLA 
plasma concentration throughout pregnancy is associated with a higher childhood BMI and other 
adiposity measures at age 6-7 [43-44]. Thus, the intervention lowering effect of DGLA content in 
placental LD could have long-term beneficial effects on childhood adiposity and obesity-related 
disorders. It is relevant that a recent report from the UPBEAT trial has reported that the intervention 
was associated with a reduction in subscapular skinfold thickness, a measure of adiposity [18]. 
Moreover, DGLA PC species were positively associated with GWG. Excessive GWG has been 
associated with increased risk of obesity, type II diabetes and metabolic syndrome in the mother and 
in offspring obesity, and might induce early programming of obesity in the fetus [45-46]. GWG was 
reduced in the main UPBEAT study [21], although it was similar between groups in the small set of 
subjects considered in the present study. 
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Despite no major differences in PCs and SMs pattern by randomisation arm, SM.24.2 was 
positively associated with birthweight and some skinfolds at birth. The relevance of this observation 
is not clear, although it is of interest that a recent study reported an association between maternal 
plasma 24:2n-6 concentration during pregnancy and the child’s diastolic blood pressure [47]. 
We carried out further analyses in the combined (intervention and control arm) placenta 
samples to gain further insight into FA handling by the placenta. The inverse association between 
placental weight and LC-PUFA containing PCs (such as those carrying DHA and ARA), indicates a 
lower LC-PUFA content in LD of larger placentas. Higher placental thickness and size are 
associated with maternal obesity, GDM and birthweight [48-49] and it would appear increased size 
may alter the capacity for placenta transfer of LC-PUFA to the fetus. This is supported by a recent 
cohort study of 435 mothers and offspring, in which the pre-pregnancy BMI was inversely 
associated with decreased PUFAs in the offspring at birth, both n-6 and DHA [50]. Maternal obesity 
is reported to modify some placental genes related to lipid transfer and intracellular lipid 
metabolism including adipose triglyceride lipase, FA transporter proteins (FATPs) 1 and 3, perlipin 
2, peroxisome proliferator-activated receptor G (PPARG) and FA binding protein 4 (FABP 4) [31, 
34], but none of these is involved in the selective transfer of DHA in placenta. More studies are 
needed to better understand the extent of maternal obesity on essential FA transfer and its influence 
on the long-term health of the newborns. 
MFSD2a protein was recently described as one of the major carriers of Lyso-DHA transport 
across the blood brain barrier [51]. MFSD2a expression in placenta has also been related to DHA-
containing metabolites in cord blood from women with GDM [30]. Our finding that MFSD2a was 
inversely associated with total LD FA content is indicative of lower expression with increasing fat 
stores in placenta. Surprisingly, Lyso-DHA in placental LD and cord blood showed a positive 
association, while no relationship was evident for any other Lyso-PCs analyzed. This may indicate 
that lyso-phospholipids can cross the placenta without further hydrolisis. Lyso-DHA has been 
proposed as a preferred carrier of DHA for red blood cells and the brain, and appears to act as a 
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DHA carrier also in placenta [52-54]. An n involvement of LD in the transfer of FAs, especially 
DHA, seems possible in placenta. However, more studies are needed to confirm this hypothesis. 
Strengths of the study include the rigour of sample collection in the setting of a large 
randomized control trial in which a rich data set of maternal variables and newborn anthropometric 
parameters were available. The lipidome of placental LD has been described for the first time.  A 
limitation is the small sub-set of subjects who provided placenta samples (n=43) which limits the 
statistical power. 
5. Conclusions 
In summary we have described for the first time the FAs composition of placental LD. We 
conclude that the placental LD composition may be modestly modified by maternal life style. The 
observation of a lower proportion of DGLA LD PCs in the intervention arm, a FA associated with 
obesity and insulin resistance, could have repercussions for obesity in later life. We also propose 
that DHA transport may be influenced by placental size and that placenta LD may play a role in the 
transfer to the fetus of some specific FAs such as DGLA, ARA and DHA. 
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Table 1. Characteristics of the mothers and neonates. 
 Intervention (n = 20) Control (n = 23) P 
Maternal 
Maternal pregestational BMI (Kg/m
2
) 
 
34.50 ± 5.08 
 
33.78 ± 3.49 
 
0.599 
Gestational weight gain (Kg) 6.86 ± 1.15 8.59 ± 0.98 0.261 
Dietary glycaemic index 52.95 ± 1.05 57.86 ± 0.88 0.001 
Maternal TG (mmol/L) 1.86 ± 0.13 2.25 ± 0.13 0.044 
Maternal total cholesterol (mmol/L) 6.15 ± 0.23 6.26 ± 0.22 0.732 
Maternal LDL cholesterol (mmol/L) 3.54 ± 0.21 3.78 ± 0.19 0.397 
Maternal HDL cholesterol (mmol/L) 2.18 ± 0.14 1.97 ± 0.09 0.188 
Placental weight (g) 620.75 ± 149.03 650.43 ± 107.09 0.453 
Caesarean section rate (%) 55.00 56.52 0.920 
Infant    
Birth weight (g) 3289.75 ± 83.75 3590.43 ± 77.39 0.012 
Birth length (cm) 49.99 ± 0.59 50.25 ± 0.90 0.826 
Birth abdominal circumference (cm) 31.18 ± 0.46 32.47 ± 0.38 0.036 
Birth mid arm circumference (cm) 11.20 ± 0.26 11.69 ± 0.23 0.172 
Results are expressed as means ± SEM. 6mo, 6 months old follow up. Significantly different at P 
<0.05. 
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Table 2. Phosphatidylcholines (PCs), sphingomyelins (SMs)
 a
 and lysophosphatidylcholines 
(LysoPCs) in placental lipid droplets from obese pregnant women randomized to a complex 
behavioural intervention, comprising nutrition and physical activity, during pregnancy or to routine 
antenatal care (control). Intervention: n=20, control: n=23. 
 
%  Intervention (n=20)  Control (n=23)  P 
PC           
PC.32:0 (16:0/16:0) 12.53 ± 0.61  11.44 ± 0.39  0.262 
PC.32:1 (16:0/16:1) 1.64 ± 0.06  1.69 ± 0.08  0.647 
PC.34:1 (16:0/18:1n-9) 9.02 ± 0.33  9.74 ± 0.30  0.107 
PC.34:2 (16:0/18:2n-6) 11.39 ± 0.34  11.43 ± 0.40  0.947 
PC.36:1 (18:0/18:1n-9) 1.34 ± 0.07  1.41 ± 0.05  0.417 
PC.36:2 (18:0/18:2n-6) 4.92 ± 0.13  5.07 ± 0.17  0.492 
PC.36:3 (16:0/20:3n-3) 6.34 ± 0.20  6.97 ± 0.21  0.037 
PC.36:4 (16:0/20:4n-6) 17.28 ± 0.47  16.97 ± 0.47  0.638 
PC.38:3 (18:0/20:3n-3) 1.33 ± 0.07  1.56 ± 0.08  0.037 
PC.38:4 (18:0/20:4n-6) 6.55 ± 0.23  6.67 ± 0.11  0.617 
PC.38:5 (18:0/20:5n-3)
 §
 4.43 ± 0.13  4.58 ± 0.14  0.433 
PC.38:6 (18:2/20:4n-6) 4.02 ± 0.14  3.93 ± 0.14  0.652 
PC.40:6 (18:0/22:6n-3) 0.89 ± 0.04  0.94 ± 0.04  0.446 
PC.32:0* (16:0/16:0*) 1.02 ± 0.07  0.92 ± 0.04  0.235 
PC.32:1* (16:0/16:1n-9*) 0.93 ± 0.06  0.82 ± 0.03  0.117 
PC.34:1* (16:0/18:1n-9*) 1.21 ± 0.04  1.13 ± 0.03  0.136 
PC.36:5* (16:0/20:5n-3*)
†
 1.02 ± 0.03  0.96 ± 0.03  0.141 
PC.38:5* (18:0/20:5n-3*)
§
 0.98 ± 0.04  1.02 ± 0.03  0.417 
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PC.40:0* (16:0/24:0*) 1.84 ± 0.09  1.95 ± 0.07  0.352 
PC.40:1* (16:0/24:1n-9*) 1.05 ± 0.05  0.96 ± 0.05  0.229 
SM           
15:0 
16:0 
16:1n-7 
17:0 
18:0 
18:1n-9 
20:0 
20:1n-9 
22:0 
22:1n-9 
23:0 
23:1n-9 
24:0 
24:1n-9 
24:2n-6 
SFA SMs 
MUFA SMs 
PUFA SMs 
1.25 ± 0.08  1.21 ± 0.06  0.644 
37.96 ± 0.76  37.06 ± 0.54  0.310 
3.58 ± 0.11  3.87 ± 0.09  0.043 
0.94 ± 0.05  0.78 ± 0.04  0.014 
4.71 ± 0.22  4.80 ± 0.13  0.753 
1.63 ± 0.09  1.75 ± 0.07  0.280 
4.03 ± 0.28  4.19 ± 0.22  0.637 
2.14 ± 0.13  2.42 ± 0.11  0.115 
12.61 ± 0.42  11.61 ± 0.38  0.080 
3.65 ± 0.18  4.10 ± 0.16  0.065 
2.11 ± 0.09  2.20 ± 0.09  0.458 
0.96 ± 0.08  0.95 ± 0.05  0.916 
9.61 ± 0.30  9.22 ± 0.29  0.354 
8.96 ± 0.23  9.49 ± 0.20  0.081 
4.04 ± 0.19  4.45 ± 0.17  0.111 
74.21 ± 0.58  72.11 ± 0.39  0.003 
21.23 ± 0.45  22.89 ± 0.33  0.003 
4.56 ± 0.20  5.00 ± 0.19  0.123 
LysoPC          
16:0 
18:0 
18:1n-9 
    29.83 ± 3.01  30.97 ± 2.69  0.775 
11.25 ± 1.04  9.78 ± 0.72  0.226 
3.97 ± 0.72  6.83 ± 0.77  0.011 
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18:2n-6 
20:3n-6 
20:4n-6 
20:5n-3 
22:6n-3 
SFA LysoPCs 
MUFA LysoPCs 
PUFA LysoPCs 
14.59 ± 1.75  13.25 ± 1.59  0.567 
6.44 ± 1.00  5.85 ± 1.10  0.695 
24.73 ± 3.12  24.52 ± 2.31  0.954 
3.98 ± 0.90  3.90 ± 0.85  0.951 
5.20 ± 0.71  4.91 ± 0.68  0.760 
41.08 ± 3.58  40.75 ± 3.08  0.944 
3.97 ± 0.72  6.83 ± 0.77  0.011 
54.95 ± 3.67  52.42 ± 3.10  0.591 
a
Only metabolites >0.9% content are listed. 20 PCs ester-linked, 25 PCs ether-linked and 5 SMs 
<0.9% are not listed. SFA, saturated fatty acids. Results are expressed as means ± SEM. *ether-
linked PCs. 
§
This metabolite can be also composed by 16:0/22:5 and 
†
by 18:1/20:4. Significantly 
different at P <0.05. 
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Table 3. Correlations between the same metabolites measured in placental lipid droplets (LD) and 
in cord blood. 
Metabolite  R P 
PC.32:0 (16:0/16:0)  0.309 0.076 
PC.32:1 (16:0/16:1n-9) 0.022 0.189 
PC.34:1 (16:0/18:1n-9) 0.395 0.021 
PC.34:2 (16:0/18:2n-6) 0.443 0.009 
PC.36:1 (18:0/18:1n-9) -0.005 0.978 
PC.36:2 (18:0/18:2n-6) 0.336 0.052 
PC.36:3 (16:0/20:3n-6) 0.598 <0.001 
PC.36:4 (16:0/20:4n-6) 0.636 <0.001 
PC.38:3 (18:0/20:3n-6) 0.348 0.044 
PC.38:4 (18:0/20:4n-6) 0.695 <0.001 
PC.38:6 (18:2/20:4n-6) 0.340 0.049 
PC.40:6 (18:0/22:6n-3) 0.491 0.014 
 LysoPC.16:0 0.125 0.480 
 LysoPC.18:0 0.270 0.123 
 LysoPC.18:1n-9 0.004 0.903 
 LysoPC.18:2n-6 0.118 0.701 
 LysoPC.20:3n-6 0.036 0.841 
 LysoPC.20:4n-6 0.050 0.779 
 LysoPC.22:6n-3 0.476 0.004 
LysoPC, lyso-phosphatidylcholine; PC, phophatidylcholine. N=43. Statistically significant at P 
<0.05. 
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Fig. 1. A) TG and B) cholesterol content (Chol) of placental lipid droplets from obese pregnant 
women randomized to a complex behavioural intervention, comprising nutrition and physical 
activity, during pregnancy or to routine antenatal care (control). C) Correlation between total FAs 
and TG content in lipid droplets (Intervention: crosses, R= 0.418, P= 0.107; control: dots, R= 0.736, 
P< 0.001). Differences statistically significant when P<0.05. Mean ± SEM. Intervention: n=20, 
control: n=23. Total correlation analysis: n=43. 
 
Fig. 2. Total FAs composition of placental lipid droplets (LD) from obese pregnant women 
randomized to a complex behavioural intervention, comprising nutrition and physical activity, 
during pregnancy or to routine antenatal care (control). Significant differences between groups, 
P<0.05. Means ± SEM. Only >1% FA are plotted, other 12 FAs were quantified (<1%): 18:3, 20:1, 
20:2, 20:5, 22:3, 22:4, 22:5, 24:3, 24:4, 24:5, 26:1 and 26:3. Intervention: n=20, control: n=23. 
 
Fig. 3. Correlation between placental weight and lipid droplets metabolites: A) PC composed of 
stearic acid (SA, 18:0) and arachidonic acid (ARA, 20:4n-6) (Intervention: R= -0.409, P= 0.103; 
control: R= -0.326, P= 0.129), B) PC composed of linoleic acid (LA, 18:2n-6) and ARA 
(Intervention: R= -0.513, P= 0.035; control: R= -0.589, P= 0.003), C) PC composed of SA and 
docosahexaenoic acid (DHA, 22:6n-3) (Intervention: R= -0.396, P= 0.116; control: R= -0.444, P= 
0.038). Intervention: crosses (n=20), control: dots (n=23). Significance, P<0.05. Total correlation 
analysis: n=43. 
 
Fig. 4. A) MFSD2a expression (arbitrary units) in placenta of obese pregnant women participating 
in a randomized controlled trial of a complex behavioural intervention, B) correlation between 
MFSD2a expression and total FAs content of placental lipid droplets (LD) (Intervention: R= -0.451, 
P= 0.091; control: R= -0.363, P= 0.089), and C) cord blood phosphatidylcholine (PC) carrying 
stearic (SA, 18:0) and DHA (22:6n-3) (Intervention: R= 0.358, P= 0.173; control: R= 0.299, P= 
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0.201). Intervention (n=20): crosses, control (n=23): dots. Total correlation analysis: n=43. 
Significance, P<0.05. N=43. 
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HIGHLIGHTS 
LD of placenta are composed mainly of saturated fatty acids. 
The behavioral intervention lowered dihomo-ɣ-linolecnic acid content in placental LD. 
Higher placental weight is associated with lower PCs carrying DHA and ARA in LD. 
Placental LD metabolites correlate with those in cord blood, especially LC-PUFA. 
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